---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-25-000010"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:40:04.703107+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)

## Summary
- CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.
- Mark S. Verratti promoted to COO effective April 30, succeeding Raha.
- Q4 2024 revenue $211M (+7% YoY); full-year revenue $838M (+11% YoY). GAAP net loss $43M (Q4) and $127M (FY).
- Adjusted EBITDA Q4 $11M, FY $40M; 2025 guidance reaffirmed: revenue $840-$860M, adjusted EPS $0.07-$0.11.
- Exclusive license of PATHOMIQ AI platform for prostate cancer; commercial launch planned later in 2025.

## SEC filing metadata
- accession: 0000899923-25-000010
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/mygn-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-25-000010
- JSON: https://secwatch.observer/filing/0000899923-25-000010.json
- Plain text: https://secwatch.observer/filing/0000899923-25-000010.txt

## Key facts
- Executive change
  Samraat S. Raha was appointed as President and Chief Executive Officer at MYRIAD GENETICS INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm
- Executive change
  Samraat S. Raha was appointed as Director at MYRIAD GENETICS INC.
  - Action: appointed
  - Role: Director
  source text: the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm
- Executive change
  Paul J. Diaz departed as President and Chief Executive Officer at MYRIAD GENETICS INC.
  - Action: stepped down
  - Role: President and Chief Executive Officer
  source text: Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.